Pneumonitis from immune checkpoint inhibitors and COVID-19: current concern in cancer treatment
Open Access
- 21 July 2020
- journal article
- editorial
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 8 (2), e000952
- https://doi.org/10.1136/jitc-2020-000952
Abstract
Pneumonitis is a rare but serious adverse event caused by cancer immunotherapy. The diagnosis between COVID-19-induced pneumonia and immunotherapy-induced pneumonitis may be challenging in the era of COVID-19 outbreak. Some clinical symptoms and radiological findings of pneumonitis can be attributed to the coronavirus infection as well as to an immune-related adverse event. Identifying the exact cause of a pneumonitis in patients on treatment with immunotherapy is crucial to promptly start the most appropriate treatment. The proper management of immune checkpoint inhibitors for the risk of pneumonia must take into account a series of parameters. Accurate attention should be payed to symptoms like cough, fever and dyspnea during immunotherapy.This publication has 15 references indexed in Scilit:
- Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, ChinaAllergy, 2020
- CT Features of Coronavirus Disease 2019 (COVID-19) Pneumonia in 62 Patients in Wuhan, ChinaAmerican Journal of Roentgenology, 2020
- There may be virus in conjunctival secretion of patients with COVID‐19Acta Ophthalmologica, 2020
- Clinical characteristics of laboratory confirmed positive cases of SARS-CoV-2 infection in Wuhan, China: A retrospective single center analysisTravel Medicine and Infectious Disease, 2020
- The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreakJournal of Autoimmunity, 2020
- Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injuryThe Lancet, 2020
- Clinical and Histopathologic Features of Immune Checkpoint Inhibitor-related PneumonitisThe American Journal of Surgical Pathology, 2019
- Clinical features, diagnostic challenges, and management strategies in checkpoint inhibitor-related pneumonitisCancer Management and Research, 2017
- Pneumonitis in Patients Treated With Anti–Programmed Death-1/Programmed Death Ligand 1 TherapyJournal of Clinical Oncology, 2017
- Incidence of Programmed Cell Death 1 Inhibitor–Related Pneumonitis in Patients With Advanced CancerJAMA Oncology, 2016